161 results
8-K
EX-99.1
ITCI
Intra-Cellular Therapies, Inc.
7 Aug 24
Intra-cellular Therapies Reports Second Quarter 2024
7:49am
. In addition, patient enrollment is ongoing in our double-blind, placebo-controlled study in bipolar depression and in our open-label safety study … ascending dose study in healthy volunteers is ongoing. The objective of this study is to evaluate pharmacokinetics, safety, and tolerability
8-K
EX-99.1
ITCI
Intra-Cellular Therapies, Inc.
18 Jun 24
Other Events
7:37am
, a patient self-reported measure of symptom severity of depression (p<0.0001)
Favorable safety and tolerability profile generally consistent … that the efficacy results from Studies 501 and 502, along with the favorable safety and tolerability profiles from these studies, will make lumateperone
8-K
EX-99.1
ITCI
Intra-Cellular Therapies, Inc.
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
with autism spectrum disorder. Additionally, the program includes an open-label safety study in schizophrenia and bipolar disorder. Patient enrollment … is ongoing in the open-label safety study as well as in the double-blind, placebo-controlled study in bipolar depression. We expect to begin patient
8-K
EX-1.1
zl9iq
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
424B5
ca2w vm32fin2j
18 Apr 24
Prospectus supplement for primary offering
5:23pm
8-K
EX-99.2
wfy72m98zl3dy3hu
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
424B5
2kp1ds7rfv10c791
16 Apr 24
Prospectus supplement for primary offering
4:37pm
S-3ASR
jwwx6sckv9
16 Apr 24
Automatic shelf registration
4:01pm
8-K
8hwo3zb
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
2xwnyuv
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
r7h4q65a
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
v5aw yc69vlh2xmoq8j0
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
7jjr5
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am